USCACA at the 6th Chinese Conference on Oncology

(Shanghai, May 22^nd, 2010). USCACA delegation joined their Chinese colleagues at the 6^th Chinese Conference on Oncology. This biannual meeting is organized by Chinese Anti-Cancer Association with a broad spectrum of topics from basic cancer research, clinical practices, to novel drug research and development. USCACA representatives include USCACA Scientific Advisor Dr. Anthony Tolcher, Director of Clinical Research at START (South Texas Accelerated Research Therapeutics), USCACA Managing Director Dr. Li Yan, and USCACA China Executive Mr. Pascal Qian.  Dr. Tolcher gave a lecture on early phase oncology drug clinical development in the session jointly organized by the CACA Anti-Cancer Drug Committee and Hutchison MediPharma. He shared with the audience his 20-year experience in early phase cancer drug development. His presentation, "Translational Medicine in Oncology Drug Development: Successes and Lessons Learned", brought a realistic view of the value of translational research. He also encouraged domestic pharmaceutical and biotechnology companies to work closely with clinical investigators to expedite oncology drug development, innovate the industry, and aspire to become global players. Dr. Jian Ding, Chairman of the CACA Anti-Cancer Drug Committee gave the closing remarks. He highly welcomed this lecture and further emphasized the necessity to fully evaluate the value proposition of any translational research before embarking the approach.